EG1 (EG-1) is a novel and potent inhibitor of Pax2 (Paired box 2) transcription activation, which targets the DNA binding domain and inhibits embryonic kidney development. It may be good lead compounds for developing tissue and cell-type specific anticancer therapies.
Physicochemical Properties
| Molecular Formula | C22H18N2O5 |
| Molecular Weight | 390.395 |
| Exact Mass | 390.121 |
| CAS # | 693241-54-2 |
| PubChem CID | 2193203 |
| Appearance | Off-white to yellow solid powder |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 490.9±40.0 °C at 760 mmHg |
| Flash Point | 250.7±27.3 °C |
| Vapour Pressure | 0.0±1.3 mmHg at 25°C |
| Index of Refraction | 1.695 |
| LogP | 3.98 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 6 |
| Heavy Atom Count | 29 |
| Complexity | 588 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O(C)C1C=CC=CC=1C(NC1C=CC(C(NC2C=CC=CC=2C(=O)O)=O)=CC=1)=O |
| InChi Key | GYZZRJRJYVMXNS-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C22H18N2O5/c1-29-19-9-5-3-7-17(19)21(26)23-15-12-10-14(11-13-15)20(25)24-18-8-4-2-6-16(18)22(27)28/h2-13H,1H3,(H,23,26)(H,24,25)(H,27,28) |
| Chemical Name | 2-[[4-[(2-methoxybenzoyl)amino]benzoyl]amino]benzoic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | EG1 (0–12.5 μM; 48 hours) increases renal pelvic system activity while decreasing Pax2 [1]. Pax2-mediated EGFP expression can be inhibited by EG1 (0-500 μM), whereas Pax2 protein levels remain unaffected [1]. |
| Cell Assay |
Cell viability assay [1] Cell Types: Pax2 positive: renal cell carcinoma cell line (RCC111), ovarian cancer cell line (TOV112D and ES-2); Pax2 negative: prostate cell line 22Rv1, PC3 or ovarian cancer cell line SK -OV-3 Tested Concentrations: 0, 12.5, 25 μM Incubation Duration: 48 hrs (hours) Experimental Results: All Pax2-positive cells demonstrated a significant decrease in cell viability, while no Pax2-negative cells were affected. |
| References | [1]. Grimley E, et al. Inhibition of Pax2 Transcription Activation with a Small Molecule that Targets the DNA Binding Domain. ACS Chem Biol. 2017;12(3):724-734. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~83.33 mg/mL (~213.45 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (5.33 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.33 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5615 mL | 12.8074 mL | 25.6148 mL | |
| 5 mM | 0.5123 mL | 2.5615 mL | 5.1230 mL | |
| 10 mM | 0.2561 mL | 1.2807 mL | 2.5615 mL |